Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 26, 2026

Back to today

How to Read a 10-K Like a Short Seller

A four-layer 10-K framework tests revenue timing, receivables, reserves and depreciation against cash flow, using Hertz’s 2012-14 accounting as a case study.

HTZ $738M
Jimmy's Journal 54 clicks

From X

@StableBread 1 click

Fajasy on X

Boost Run $BRUN said on October 26 that it has closed "more than $600 million in non-dilutive project financing" so far in 2026. In my October 19 update, I said the stock depends less on demand than on whether $BRUN can finance the next ~$1B of GPUs without selling shares at beaten-down prices. The release also says: → $BRUN has established "a fully funded runway to accelerate customer deployments through the fourth quarter of 2026," with additional financing "proceeding as planned." → $BRUN delivered the first phase of a multi-phase project to "a leading AI research and product company," which matches its $471.7M May 2026 contract with Thinking Machines Lab (Mira Murati's AI startup). → Several more projects are "nearing hand-off in the coming weeks." → Founder and CEO Andrew Karos: "Customer payments exceed our debt payments every month." The $600M+ is YTD, and lessors funded $268.3M of new GPU leases in H1 2026 alone. So if those leases count toward the $600M+, $BRUN has closed more than $331.7M since June 30, about half to almost two-thirds of the $527-686M of new leases I estimated its H2 2026 build needs. The release doesn't say what the financing costs or how much of it closed since June 30. However, the Q3 10-Q, expected in mid-November, should disclose how much $BRUN leased in Q3 and at what rate. If the 10-Q confirms the $600M+, I'd drop the $62.2M stock sale from my bear case, and the question shifts from whether $BRUN can fund its build to what the new debt costs.
@StableBread 4 clicks

Fajasy on X

At CAD$1.98/share (October 23 close), you’re paying US$214-265M for Levack, the flagship restart project of Magna Mining $MGMNF (TSX: $NICU), or 62-76% of the enterprise value. On the 336.57M diluted count, Magna’s market cap is US$476M, and here’s how it breaks down: → Cash, incl. option proceeds: US$130M (CAD$0.54/share) → McCreedy West, the producing mine: US$28-43M (CAD$0.11-0.18/share) → Crean Hill, the permitted nickel mine: US$54-90M (CAD$0.22-0.37/share) → Levack, R2 (a high-grade zone at Levack), and the rest (implied): US$214-265M (CAD$0.89-1.10/share) For McCreedy West, I valued 3-5 years of margin, discounted at 8%. For Crean Hill, I applied 0.3-0.5x the US$179M after-tax NPV in its October 20 pre-feasibility study. To estimate how much Levack has to produce each year to justify the CAD$1.98 share price, I assumed: → Margin: US$1.85/payable lb before taxes. I started with McCreedy West’s Q2 cash margin of US$1.41/lb, subtracted US$0.42/lb of H1 sustaining capital, and added back the US$0.86/lb the precious metals stream took in Q2. CEO Jason Jessup said most of the tons in Levack’s October 7 preliminary economic assessment (PEA) would come from the contact zones, which I assume sit outside the stream, since the PEA release doesn’t say how much ore the stream covers. → Timing: 7.3 years of output starting in mid-2028, per the PEA. → Taxes: 27% of the value, the share Levack’s PEA loses to taxes. → Discount rate: 8%. On these assumptions, US$214-265M requires 32-40M payable lbs/year from Levack before restart capital (the upfront spending to rebuild and reopen the mine). The PEA’s CAD$70.1M of initial capital adds ~7.5M lbs/year to the requirement, but pre-commercial cash flow and tax credits cut the net funding need to CAD$8.6M, or ~1M lbs/year. Jessup had said Levack could produce 2-3x McCreedy West’s output. The PEA plans 36.8M payable lbs/year from mid-2028 to 2035, ~2.2x McCreedy West’s 17M lbs guidance midpoint. So at Q2 margins, CAD$1.98 assumes close to the PEA’s output, which leaves out R2. But 2.1M of the PEA’s 5.75M short tons are inferred resources (from more widely spaced holes), so over a third of the plan rests on less certain tonnes. However, a 10% higher realized price adds US$0.60/lb to the margin and cuts the requirement to 24-30M lbs/year, well below the PEA’s 36.8M. Since Q2, copper is up 8.3% from Magna’s average ($6.54/lb vs. $6.04), while nickel is down 13.5% ($7.12 vs. $8.23). Nickel is 46.0% of the PEA’s revenue and copper 34.8%, so for Levack, nickel’s drop outweighs copper’s gain. In other words, higher copper prices alone won’t lower what Levack has to deliver. Nickel has to recover too.
@StableBread 1 click

Fajasy on X

On EV to year-end ARR, Boost Run $BRUN now trades below CoreWeave $CRWV, Nebius $NBIS, and $IREN. At $8.89/share, $BRUN’s EV is $989.7M. That’s 2.5x its $400M target for year-end ARR, down from 5.4x at the $22.93 price in my August 16 update. EV is market cap plus debt and lease liabilities, less unrestricted cash, using October 16 closes and June 30 balance sheets ($BRUN’s cash is pro forma for the warrant exercises). ARR is the midpoint of each company’s year-end 2026 target, which is $18.5-19.5B for CoreWeave, $7-9B for Nebius, $400M for $BRUN, and more than $4B for $IREN. At 2.5x, $BRUN trades below all three peers, including $IREN at 3.2x. A reasonable range for $BRUN is 2.5-5.0x, from where it trades today to just under the midpoint of CoreWeave’s 4.2x and Nebius’s 5.9x. I use the peers’ median rather than their average, since Nebius’s 5.9x skews the average higher. Nebius also owns more than 75% of its contracted power, while $BRUN owns no data centers (a different model, not a weakness).

Investor Letters

All letters

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

LPTH $492M
Trade Ideas Flow 21 clicks

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

BMBL $787M
TSOH Investment Research 12 clicks
BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

BNTC $302M
Value Investors Club

Entravision Q2 Notes

Entravision’s ATS revenue rose 230% to $182.8 million in Q2, but shares fell from above $14 to about $8 after management forecast…

EVC $575M
The Value Road 13 clicks

40 Stock Pitches (3rd-9th August)

Navient trades near 40% of tangible book as Gator Financial Partners argues private student-loan growth and restructuring can reverse its…

NAVI $831M
Capital Employed 9 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 254

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.